BRPI0509559A - compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos - Google Patents
compostos de pirazolamina para o tratamento de distúrbios neurodegenerativosInfo
- Publication number
- BRPI0509559A BRPI0509559A BRPI0509559-0A BRPI0509559A BRPI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pyrazolamine
- treatment
- neurodegenerative disorders
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
COMPOSTOS DE PIRAZOLAMINA PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS. A presente invenção refere-se a compostos de fórmula: em que R¬ 1¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e R¬ 8¬ são como definidos acima. Os compostos de fórmula (I) apresentam atividade quando da produção de inibição de A<225>-peptídeos. A invenção também refere-se a composições farmacêuticas e a métodos de tratamento de distúrbios e doenças, por exemplo, doença de Alzheimer, em um mamífero, compreendendo os compostos de fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55890404P | 2004-04-01 | 2004-04-01 | |
PCT/IB2005/000793 WO2005095348A2 (en) | 2004-04-01 | 2005-03-21 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509559A true BRPI0509559A (pt) | 2007-09-18 |
Family
ID=34962302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509559-0A BRPI0509559A (pt) | 2004-04-01 | 2005-03-21 | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos |
Country Status (10)
Country | Link |
---|---|
US (2) | US7244757B2 (pt) |
EP (2) | EP1735285B1 (pt) |
JP (1) | JP2007530659A (pt) |
AT (1) | ATE402150T1 (pt) |
BR (1) | BRPI0509559A (pt) |
CA (1) | CA2561441A1 (pt) |
DE (1) | DE602005008417D1 (pt) |
ES (1) | ES2308442T3 (pt) |
MX (1) | MXPA06011351A (pt) |
WO (1) | WO2005095348A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
US7923465B2 (en) * | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
JP6138928B2 (ja) * | 2012-06-01 | 2017-05-31 | ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー.ファウ.(エフエルイー) | 医薬に使用されるnotchシグナル伝達経路及び分泌の阻害物質 |
EP3052096B8 (en) | 2013-10-03 | 2018-03-07 | Kura Oncology, Inc. | Inhibitors of erk and methods of use |
AU2019220662A1 (en) * | 2018-02-16 | 2020-09-03 | Constellation Pharmaceuticals, Inc. | P300/CBP HAT inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS503340Y2 (pt) * | 1971-06-17 | 1975-01-28 | ||
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
AP2001002266A0 (en) | 2000-08-31 | 2001-09-30 | Pfizer Prod Inc | Pyrazole derivatives. |
NZ525892A (en) | 2000-11-27 | 2004-11-26 | Pharmacia Italia S | Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof |
WO2003064396A1 (en) | 2002-02-01 | 2003-08-07 | Elan Pharmaceuticals, Inc. | Hydroxyalkanoyl aminopyrazoles and related compounds |
US6974829B2 (en) | 2002-05-07 | 2005-12-13 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
CA2501799C (en) | 2002-10-09 | 2008-06-17 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
BRPI0409721A (pt) | 2003-05-12 | 2006-05-02 | Pfizer Prod Inc | compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos |
WO2005009344A2 (en) * | 2003-06-05 | 2005-02-03 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
-
2005
- 2005-03-11 US US11/078,861 patent/US7244757B2/en not_active Expired - Fee Related
- 2005-03-21 WO PCT/IB2005/000793 patent/WO2005095348A2/en active IP Right Grant
- 2005-03-21 BR BRPI0509559-0A patent/BRPI0509559A/pt not_active IP Right Cessation
- 2005-03-21 EP EP05708792A patent/EP1735285B1/en not_active Not-in-force
- 2005-03-21 CA CA002561441A patent/CA2561441A1/en not_active Abandoned
- 2005-03-21 JP JP2007505655A patent/JP2007530659A/ja not_active Withdrawn
- 2005-03-21 AT AT05708792T patent/ATE402150T1/de not_active IP Right Cessation
- 2005-03-21 DE DE602005008417T patent/DE602005008417D1/de not_active Expired - Fee Related
- 2005-03-21 MX MXPA06011351A patent/MXPA06011351A/es active IP Right Grant
- 2005-03-21 ES ES05708792T patent/ES2308442T3/es active Active
- 2005-03-21 EP EP08157177A patent/EP1958939A3/en not_active Withdrawn
-
2007
- 2007-07-05 US US11/773,831 patent/US7468386B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7468386B2 (en) | 2008-12-23 |
EP1735285A2 (en) | 2006-12-27 |
WO2005095348A3 (en) | 2006-03-23 |
ATE402150T1 (de) | 2008-08-15 |
US20050222239A1 (en) | 2005-10-06 |
EP1735285B1 (en) | 2008-07-23 |
JP2007530659A (ja) | 2007-11-01 |
US7244757B2 (en) | 2007-07-17 |
MXPA06011351A (es) | 2006-12-15 |
WO2005095348A2 (en) | 2005-10-13 |
EP1958939A3 (en) | 2008-09-10 |
DE602005008417D1 (de) | 2008-09-04 |
CA2561441A1 (en) | 2005-10-13 |
EP1958939A2 (en) | 2008-08-20 |
US20070265327A1 (en) | 2007-11-15 |
ES2308442T3 (es) | 2008-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
BRPI0509504A (pt) | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos | |
MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos | |
WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
BRPI0509582A (pt) | compostos de tiazol-amina e respectivas composições farmacêuticas | |
TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
MY145068A (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
DOP2006000200A (es) | Compuestos de imidazol para el tratamiento de trastonos neurologicos | |
DOP2004000982A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
CU23591B7 (es) | Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos | |
EA200500382A1 (ru) | Соединения тиазола для лечения нейродегенеративных расстройств | |
DOP2004000970A (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2137 DE 20/12/2011. |